RESP302

DRUG2 trials

Sponsors

Thirty Respiratory Limited

Conditions

Non-Cystic Fibrosis BronchiectasisNon-Cystic Fibrosis Bronchiectasis with Pseudomonas Aeruginosa or other Potentially Pathogenic Micro-organisms

Phase 1

Phase 1/2a Trial to Evaluate the Safety, Tolerability and Efficacy of Nebulised RESP30X Nitric Oxide Formulations in Non-Cystic Fibrosis Bronchiectasis (NCFB) Patients with Pseudomonas Aeruginosa (Pa) or other Potentially Pathogenic Micro-organisms (PPMs).

Not yet recruitingCTIS2023-508706-23-00

Thirty Respiratory LimitedNon-Cystic Fibrosis Bronchiectasis with Pseudomonas Aeruginosa or other Potentially Pathogenic Micro-organisms

Target: 40Updated: 2025-04-30

Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)

Active, not recruitingNCT06663176

Thirty Respiratory LimitedNon-Cystic Fibrosis Bronchiectasis

Start: 2024-10-16End: 2028-05-05Target: 60Updated: 2026-03-10